子宫肌瘤是女性最常见良性肿瘤,其生长具有雌激素依赖性。连续应用促性腺激素增效剂通过抑制垂体-卵巢功能可有效造成低雌激素环境。作者等用配对安慰剂双盲实验法客观评价 GnRH 增剂 buserelin 的临床效用。99例病人,年龄28～56岁,随机分为二组(buserelin 组49例,安慰剂组50例)。每天静脉应用 buserelin 900μg,共16周。 Uterine fibroids are the most common benign tumors in women and their growth is estrogen-dependent. Continuous application of gonadotropin synergist can effectively result in a low estrogen environment by inhibiting pituitary-ovarian function. The authors used the paired placebo double-blind experimental method to objectively evaluate the clinical utility of GnRH augmentation buserelin. Ninety-nine patients, aged 28-56, were randomized to two groups (49 in the buserelin group and 50 in the placebo group). Buserelin 900 μg intravenously daily for 16 weeks.